Compare Agnico Eagle Mines Ltd (AEM) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs AstraZeneca plc — how do they compare? Agnico Eagle Mines Ltd trades at $185.41 (market cap $92.01B), while AstraZeneca plc trades at $158.36 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 2.7× Agnico Eagle Mines Ltd's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AEM | AZN | |
|---|---|---|
Market Cap | $92.01B | $248.14B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $209.48 |
52-Week Low | $130.23 | $147.06 |
Enterprise Value | $88.85B | $275.41B |
Dividend Yield | 0.99% | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $180.48, up 0.93% today, with strong quarterly earnings beats and bullish analyst consensus. The stock shows robust fundamentals with a P/E of 15.56, net income margin of 40.44%, and record free cash flow of $6.82B in 2025. Recent news highlights operational strength amid gold price gains, though cost pressures are noted.
Outlook remains positive with a $219.63 price target and 67.7% buy ratings, supported by organic growth plans. Risks include rising production costs and gold price volatility. The stock offers upside potential but faces margin compression headwinds in 2026.
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
